Relmada Therapeutics said it remains on track to start its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer. The company also strengthened its balance sheet through a private financing, improving funding visibility for the development timeline. The update is supportive but still early-stage and unlikely to be a major near-term market mover.
Relmada Therapeutics said it remains on track to start its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer. The company also strengthened its balance sheet through a private financing, improving funding visibility for the development timeline. The update is supportive but still early-stage and unlikely to be a major near-term market mover.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
